Loading..
  • Oasmia logo
  • Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact
  • About Us
    • Purpose, Vision & Mission
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Collaborations and partners
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Our Science
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Portfolio
      • Docetaxel Micellar
      • XR-19
    • Animal Health
    • Research and development
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Investment case
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2015
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
December 7, 2015

Oasmia Pharmaceutical’s Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials

Non Regulatory
December 3, 2015

Interim report for the period May – October 2015

Regulatory
November 30, 2015

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory
November 20, 2015

Oasmia Pharmaceutical’s Lead Human Cancer Drug Paclical® Generates Strong Interest at the 19th Annual Russian Cancer Congress

Non Regulatory
November 5, 2015

Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory
November 5, 2015

Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment

Non Regulatory
October 30, 2015

Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market

Non Regulatory
October 29, 2015

Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing

Non Regulatory
October 28, 2015

Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market

Regulatory
October 23, 2015

Nexttobe extends loan to Oasmia

Non Regulatory
October 23, 2015

Oasmia Pharmaceutical AB Announces Pricing of Public Offering of American Depositary Shares and NASDAQ Listing

Non Regulatory
October 20, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering

Non Regulatory
October 5, 2015

Oasmia Pharmaceutical AB Announces Commercial Launch of Paclical in Russia and CIS Countries

Non Regulatory
September 30, 2015

Communiqué from Oasmia’s Annual General Meeting 2015

Non Regulatory
September 28, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants

Regulatory
September 5, 2015

Interim report for the period May – July 2014

Non Regulatory
September 3, 2015

Interim report for the period May – July 2015

Regulatory
August 31, 2015

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

Non Regulatory
August 21, 2015

The Oasmia Pharmaceutiacal Annual Report is now published

Non Regulatory
August 17, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow

Non Regulatory
August 4, 2015

Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory
August 3, 2015

Oasmia Pharmaceutical Extends Form F-1/A Registration Statement to Include New Key Material Data and Final Full-Year Financials

Non Regulatory
July 7, 2015

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing

Non Regulatory
July 7, 2015

Oasmia Pharmaceutical Launches US Brand and Sales Platform

Non Regulatory
July 4, 2015

Year-end report for the fiscal year May 2014 – April 2015

Non Regulatory
May 29, 2015

Changes in Oasmia’s Board of Directors and Management

Regulatory
May 29, 2015

Communiqué from Oasmia’s Extraordinary General Meeting 2015

Non Regulatory
May 7, 2015

Oasmia gives notice of Extraordinary General Meeting

Regulatory
May 7, 2015

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)

Non Regulatory
April 24, 2015

Results from Oasmia’s Phase III study will be presented at ASCO

Regulatory
April 20, 2015

Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation

Non Regulatory
March 5, 2015

Interim report for the period May 2014 – January 2015

Non Regulatory
February 17, 2015

Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma

Investor contact

Cord Communications
IR@oasmia.com
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com